Baseline HCC Patient Characteristics
| Parameter | n (%) |
| Demographics | |
| Number of patients | 23 (100) |
| Age (y), mean ± SD | 62.39 ± 8.62 |
| Male/female | 18 (78.26)/5 (21.74) |
| Ethnicity | |
| Caucasian | 18 (78.26) |
| Asian | 1 (4.35) |
| African-American | 4 (17.39) |
| Disease characteristics | |
| Etiology of cirrhosis | |
| Viral hepatitis | 17 (73.91) |
| Alcohol consumption | 4 (17.39) |
| Nonalcoholic steatohepatitis | 2 (8.7) |
| Eastern Cooperative Oncology Group performance status | |
| 0 | 11 (47.83) |
| 1 | 12 (52.17) |
| Child–Pugh class | |
| A | 13 (56.52) |
| B | 10 (43.48) |
| Barcelona Clinic liver cancer stage | |
| B | 10 (43.45) |
| C | 13 (56.52) |
| Main portal vein thrombosis | 5 (21.74) |
| Extrahepatic disease | 3 (13.04) |
| Tumor characteristics, median (interquartile range, range) | |
| Number of tumors/liver | 6 (3.5–12, 1–54) |
| Number of tumors/analyzed lobe | 4 (2–5, 1–11) |
| TTV (cm3)/analyzed lobe | 110.08 (79.82–225.58, 4.13–730.37) |
| ETV (cm3)/analyzed lobe | 62.57 (7.47–112.8, 0–509.95) |
| Tumor burden (%)/analyzed lobe | 13.05 (5.12–28.78, 0.71–67.56) |
| Enhancing tumor burden (%)/analyzed lobe | 4.34 (0.83–12.41, 0–57.82) |
| Previous treatments | |
| Sorafenib | 5 (21.74) |
| Resection* | 3 (13.04) |
| TACE* | 11 (47.83) |
| Ablation* | 5 (21.74) |
| Other | 5 (21.74) |
↵* Pretreated tumors are not included in the analysis.